Inhaled Amikacin Reduces Ventilator-Associated Pneumonia in Critically Ill Patients
Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia
This clinical trial investigated whether inhaled amikacin, an antibiotic, could reduce the incidence of ventilator-associated pneumonia in critically ill patients on mechanical ventilation for at least 3 days. The study included 847 patients who received either inhaled amikacin or a placebo for 3 days. Results showed that inhaled amikacin reduced the occurrence of ventilator-associated pneumonia by 15% compared to the placebo group. Additionally, the treatment was associated with fewer infection-related complications and had a favorable safety profile.
